USAMRICD TECH MEMO 90 1 CLINICAL NOTES ON CHEM CASUALTY CARE

File: 970101_sep96_decls27_0010.txt
Page: 0010
Total Pages: 22

Subject: USAMRICD TECH MEMO 90 1 CLINICAL NOTES ON CHEM CASUALTY CARE    

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003205

Folder Title: CLINICAL NOTES ON CHEMICAL CASUALTY CARE                                                        

Document Number:          1

Folder Seq  #:         31








            u    CD Technical Memorandum 90-1


               isystom effects (GI, muscular,
               spiratory, etc: within one hour: 3         I?S
               ter 1-2 hours: 2-3 MARK I's

            NOTE: DIAZEPAM SHOULD BE GIVEN WITH THIRD        I WHEN THREE ARE
                 TOGETHER


            4RIDOSTIGMINE PRETREATMENT FOR NERVE AGENTS
            I
            GfN
            i@ taken before nerve agent challenge (or poisoning) pyridostigmine
            will cause drug therapy to be more effective.       It is NOT a
            treatment for nerve agent intoxication and it will NOT prevent the
            effects of nerve agents from occurring. Drug therapy MUST be used
            iidthe usual manner for nerve agent signs and symptoms.
            prdostigmine has been developed by the tl.S. and other countries
               has been issued to military personnel of the U.S. and other
            countries for use if a nerve agent attack is perceived to be
            i@diate.
            D  RINE OF USE
            ThT7Division and corps Commanders have the authority to start and
            d scontinue the use of pyridostigmine, based on advice of
            intelligence, chemical, and medical staffs.    This need will be
            r assessed every three days, and unless circumstances are
            exceptional use should not be continued beyond 7 consecutive days.
            I
            Uoit of issue is one "blibter pack" containing 21 tablets (30 mg
            each) to each military person. Dose is 30 mg every 8 hours. If a
            d?se is missed, under no circumstances should one take two tablets
            as a "make-up" dose, but rather should start one tablet on an eight
            h@ur schedule again. If one is in MOPP IV, one should not break
            @e integrity of the ensemble to take the tablet, but should resume
            after YOPP IV is removed.
            NEED FOR PRETREATMENT
            I
menable to therapy by an
            ojirae, but that from soman is not because of the rapid "aging" of

Document 22 f:/Week-36/BX003205/CLINICAL NOTES ON CHEMICAL CASUALTY CARE/usamricd tech memo 90 1 clinical notes on chem c:12249609312728
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003205
Unit = OTSG
Parent Organization = HSC
Folder Title = CLINICAL NOTES ON CHEMICAL CASUALTY CARE
Folder Seq # = 31
Subject = USAMRICD TECH MEMO 90 1 CLINICAL NOTES ON CHEM C
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 24-DEC-1996